Mucopolysaccharidosis II
Conditions
Brief summary
A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.
Interventions
DRUGJR-141
IV infusion (lyophilized powder), 1.0 mg/kg/week
Sponsors
JCR Pharmaceuticals Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
0 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males with confirmed diagnosis of MPS II, based on deficient activity of IDS in leucocytes or fibroblasts and/or pathogenic mutations identified in the IDS gene (if enzyme diagnosis was in dried blood spots or plasma, molecular genetics confirmation is mandatory). * One of the following age groups: 1. 0 to 3 years and 11 months old (6 patients, 2 in each dose) 2. 4 years to 7 years and 11 months old (6 patients, 2 in each dose) 3. 8 years or older (6 patients, 2 in each dose) * Capable of providing written consent by himself, unless the patient is under the age of 18 years at the time of informed consent process, or it is not possible to obtain consent from the patient himself due to his intellectual disabilities associated with MPS II. * In the case of a patient who is under the age of 18 years or from whom it is not possible to obtain consent due to his intellectual disabilities associated with MSP II, he may be included if written consent can be provided by legal representative; however written consent should be obtained from the patient himself too, wherever possible. * Naïve patients or patients who are receiving enzyme replacement therapy with idursulfase could be included if provided treatment has been stable in the last 6 months and agree to interrupt the treatment at least one week before the first study drug infusion, and agree in suspending this treatment for the duration of the trial.
Exclusion criteria
* Refusal to sign the informed consent form. * Unable to perform the study procedures, except for neurocognitive testing. * Previous engrafted BMT/HSCT. * Surgical or other major medical intervention planned to occur before week 26. * Participation in a clinical trial with an investigational drug in the last 12 months. * Judged by the investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumber puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process. * Judged by the investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or sensitivity. * Otherwise judged by the investigator or subinvestigator to be ineligible to participate in the study out of consideration for the subject safety.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events | 26 weeks | * Adverse events * Antidrug antibodies * Blood pressures in mmHg * Heart rate in beats/minute * Respiratory rate in breaths/minute * Temperature in °C * Presence or absence of abnormalities for physical examination * Presence or absence of abnormalities for 12-lead electrocardiogram * Routine laboratory tests in blood (hematology, liver function, renal function, iron-related levels) and urine (urinalysis) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Pharmacokinetic parameter [Area Under the Curve [AUC]] | 21 hours after dosing at the first and last infusions | Plasma concentration of JR-141 |
| Liver and spleen volumes (MRI) | 26 weeks | — |
| Left ventricular mass by a standard 2-dimensional Doppler echocardiogram | 26 weeks | — |
| Plasma Pharmacokinetic parameter [Maximum Plasma Concentration [Cmax]] | 21 hours after dosing at the first and last infusions | Plasma concentration of JR-141 |
| Urinary dermatan sulfate concentrations | 26 weeks | — |
| Serum heparan sulfate concentrations | 26 weeks | — |
| Serum dermatan sulfate concentrations | 26 weeks | — |
| Urinary heparan sulfate concentrations | 26 weeks | — |
Countries
Brazil
Outcome results
None listed